公开(公告)号：US20250057791A1

公开(公告)日：2025-02-20

申请号：US18719379

申请日：2022-12-15

Applicant: Alexandre GURBA ,  Patrick GUERIN ,  Alexandre VERNUDACHI ,  Thomas KRÖBER

Inventor： Patrick Guerin ,  Alexandre Vernudachi ,  Thomas Kröber

IPC: A61K31/185 ,  A61K31/44 ,  A61K31/522 ,  A61K38/08 ,  G01N33/50

Abstract: This invention concerns a product comprising one or more purinergic receptor (PR) antagonist for use in prevention and/or treatment of parasitic infestation of a human and/or animal host by an arthropod parasite by exposing the arthropod parasite to one or more PR antagonist, or by contacting the arthropod parasite with one or more PR antagonist. The invention also concerns a pharmaceutical composition comprising the product for use in prevention and/or treatment of parasitic infestation of a human and/or animal host by an arthropod parasite, and screening methods to identify suitable PR antagonist.

公开(公告)号：US12208072B2

公开(公告)日：2025-01-28

申请号：US17436687

申请日：2019-02-13

Applicant: DEBx Medical Holding B.V.

Inventor： Carlo Alberto Bignozzi ,  Francesco Carinci ,  Alberto Cogo

IPC: A61K31/185 ,  A61K9/00 ,  A61K31/10 ,  A61K31/191 ,  A61K31/194 ,  A61K31/198 ,  A61K31/4184 ,  A61K31/695 ,  A61K31/77 ,  A61K33/00 ,  A61P1/02 ,  A61P17/02 ,  A61P31/04

Abstract: A composition, usable for removing a biofilm and necrotic or infected tissues from skin lesions and lesions of the oral cavity, comprises methanesulfonic acid 99.0% and a proton acceptor. The proton acceptor is selected from the group consisting of: anhydrous sodium carbonate, 5-amino-2-mercaptobenzimidazole, ethylenediaminetetraacetic acid tetrasodium salt, sodium gluconate, sodium tartrate dihydrate, 2-mercapto-5-benzimidazole sodium sulfonate, dimethyl sulfoxide, polyethylene glycol 400, polyethylene glycol 600, silicon dioxide, tetraethoxysilane, and mixtures thereof. The aforesaid composition can be prepared in the form of a solution, gel or cream.

公开(公告)号：US20240366637A1

公开(公告)日：2024-11-07

申请号：US18562865

申请日：2022-05-20

Applicant: Cancer Research and Biotechnology AG

Inventor： Kari Sarvanto

IPC: A61K31/6615 ,  A61K31/185 ,  A61K33/30 ,  C12Q1/02

Abstract: The present invention is directed to a composition or combination comprising (i) a compound inhibiting the synergistic carcinogenic effect of cadmium in the presence of another carcinogen; and (ii) optionally a heavy metal chelating or binding compound; for use in the prevention or treatment of cancer in a patient or the prevention of the recurrence of cancer in a patient. The present invention is also directed to a method for detecting anticarcinogens comprising the steps of: providing living cells in a cell culture; culturing said cells in the presence of cadmium, a carcinogen and a candidate anticarcinogen; and detecting those candidate anticarcinogens as anticarcinogens which prevent or decrease the carcinogenic effect of the combination of cadmium and the carcinogen to said cells during the culturing step.

公开(公告)号：US11992471B2

公开(公告)日：2024-05-28

申请号：US18059332

申请日：2022-11-28

Applicant: AMOREPACIFIC CORPORATION

Inventor： Phil June Park ,  Hyunsoo Kim ,  Hyoung June Kim

IPC: A61K31/185 ,  A61K9/00 ,  A61K47/02 ,  A61K47/12 ,  A61K47/36 ,  A61K47/46 ,  A61P29/00

CPC classification number: A61K31/185 ,  A61K9/0014 ,  A61K47/02 ,  A61K47/12 ,  A61K47/36 ,  A61K47/46 ,  A61P29/00

Abstract: Provided are a reelin and/or VEGF-C production and/or VEGF-C activation promoter including a compound including a sulfonic acid group and an amino group as an active ingredient, and a skin external composition including the compound.

公开(公告)号：US11987769B2

公开(公告)日：2024-05-21

申请号：US17053580

申请日：2019-05-03

Applicant: OLEON NV

Inventor： Pieter Struelens ,  Andreas Lambin ,  Dirk Packet

IPC: A61K31/23 ,  A61K8/36 ,  A61K31/185 ,  A61Q17/04 ,  A61Q19/00 ,  C10M129/32 ,  C11C3/08 ,  C11C3/14 ,  C10N20/00

CPC classification number: C11C3/14 ,  A61K8/361 ,  A61Q17/04 ,  A61Q19/00 ,  C10M129/32 ,  C11C3/08 ,  A61K2800/10 ,  C10M2207/126 ,  C10N2020/011 ,  C10N2020/071

Abstract: The present invention relates to a composition of branched fatty acids or esters thereof, the process for preparing such a composition and its use in various industrial fields, such as in lubricant, in cosmetics and in home care. More particularly, the present invention relates to a composition comprising at least 30% by weight of polybranched C10-C24 fatty acids or esters thereof, and a cyclic compound content ranging from 1% to 8% by weight, the weight percentage being given on the total weight of the composition.

公开(公告)号：US20240158532A1

公开(公告)日：2024-05-16

申请号：US18419527

申请日：2024-01-22

Applicant: Merus N.V.

Inventor： Cecilia Anna Wilhelmina GEUIJEN ,  Cornelis Adriaan DE KRUIF ,  Mark THROSBY ,  Ton LOGTENBERG ,  Alexander Berthold Hendrik BAKKER

IPC: C07K16/32 ,  A61K31/185 ,  A61K31/337 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/519 ,  A61K39/395 ,  C07K16/30

CPC classification number: C07K16/32 ,  A61K31/185 ,  A61K31/337 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/519 ,  A61K39/39558 ,  C07K16/30 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates among other to antibodies comprising a first antigen-binding site that binds ErbB-2 and a second antigen-binding site that binds ErbB-3. The antibodies can typically reduce a ligand-induced receptor function of ErbB-3 on a ErbB-2 and ErbB-3 positive cell. Also described are the method for treatment and use of antibodies in imaging and in the treatment of subjects having an ErbB-2, ErbB-3 or ErbB-213 positive tumor.

公开(公告)号：US20240156696A1

公开(公告)日：2024-05-16

申请号：US18511294

申请日：2023-11-16

Applicant: Trustees of Boston University

Inventor： Yuwei FAN ,  Lina Fahad N. MENGARI ,  Zhi SUN

IPC: A61K8/21 ,  A61K8/24 ,  A61K8/36 ,  A61K31/185 ,  A61K33/06 ,  A61K33/16 ,  A61K33/42 ,  A61Q11/00

CPC classification number: A61K8/21 ,  A61K8/24 ,  A61K8/36 ,  A61K31/185 ,  A61K33/06 ,  A61K33/16 ,  A61K33/42 ,  A61Q11/00 ,  A61K2800/596 ,  A61K2800/805 ,  A61K2800/92

Abstract: The present disclosure relates to compositions and methods for restoring enamel, e.g., on tooth surfaces.

公开(公告)号：US20240122883A1

公开(公告)日：2024-04-18

申请号：US18264200

申请日：2022-02-15

Applicant: NATIONAL JEWISH HEALTH ,  SOUTH DAKOTA STATE UNIVERSITY ,  THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

Inventor： Carl W. WHITE ,  Heidi NICK ,  Preston BRATCHER ,  Brian LOGUE

IPC: A61K31/185 ,  A61K38/49 ,  A61P39/02

CPC classification number: A61K31/185 ,  A61K38/49 ,  A61P39/02

Abstract: In one aspect, the present disclosure provides a method of treating a subject exposed to as toxic inhaled chemical, the method comprising administering to the subject a therapeutically effective amount of 2-mercaptoethane sulfonic acid, or a salt or solvate thereof. In some embodiments, the method further comprises administering to the subject a therapeutically effective amount of tissue plasminogen activator. In some embodiments, the toxic inhaled chemical is sulfur mustard, methyl isocyanate, or a combination thereof.

公开(公告)号：US11919839B2

公开(公告)日：2024-03-05

申请号：US17238529

申请日：2021-04-23

Applicant: Valo Health, Inc.

Inventor： Kenneth W. Bair ,  Nicholas Barczak ,  Bingsong Han ,  David R. Lancia, Jr. ,  Cuixian Liu ,  Matthew W. Martin ,  Pui Yee Ng ,  Aleksandra Rudnitskaya ,  Jennifer R. Thomason ,  Mary-Margaret Zablocki ,  Xiaozhang Zheng

IPC: C07C259/06 ,  A61K31/185 ,  A61K31/277 ,  A61K31/397 ,  A61K31/4035 ,  A61K31/407 ,  A61K31/417 ,  A61K31/4184 ,  A61K31/435 ,  A61K31/438 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/451 ,  A61K31/495 ,  A61K31/5377 ,  C07D207/10 ,  C07D207/267 ,  C07D209/08 ,  C07D209/42 ,  C07D209/44 ,  C07D209/46 ,  C07D211/16 ,  C07D211/58 ,  C07D213/56 ,  C07D213/65 ,  C07D213/75 ,  C07D213/81 ,  C07D215/12 ,  C07D221/20 ,  C07D231/14 ,  C07D231/18 ,  C07D233/36 ,  C07D233/38 ,  C07D233/68 ,  C07D235/14 ,  C07D235/30 ,  C07D239/20 ,  C07D239/22 ,  C07D241/08 ,  C07D241/12 ,  C07D249/18 ,  C07D257/04 ,  C07D261/18 ,  C07D277/56 ,  C07D295/155 ,  C07D295/192 ,  C07D307/68 ,  C07D317/68 ,  C07D333/70 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/04 ,  C07D409/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/10 ,  C07D493/08 ,  C07D495/10 ,  C07D498/04 ,  C07D513/10

CPC classification number: C07C259/06 ,  A61K31/185 ,  A61K31/277 ,  A61K31/397 ,  A61K31/4035 ,  A61K31/407 ,  A61K31/417 ,  A61K31/4184 ,  A61K31/435 ,  A61K31/438 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/451 ,  A61K31/495 ,  A61K31/5377 ,  C07D207/10 ,  C07D207/267 ,  C07D209/08 ,  C07D209/42 ,  C07D209/44 ,  C07D209/46 ,  C07D211/16 ,  C07D211/58 ,  C07D213/56 ,  C07D213/65 ,  C07D213/75 ,  C07D213/81 ,  C07D215/12 ,  C07D221/20 ,  C07D231/14 ,  C07D231/18 ,  C07D233/36 ,  C07D233/38 ,  C07D233/68 ,  C07D235/14 ,  C07D235/30 ,  C07D239/20 ,  C07D239/22 ,  C07D241/08 ,  C07D241/12 ,  C07D249/18 ,  C07D257/04 ,  C07D261/18 ,  C07D277/56 ,  C07D295/155 ,  C07D295/192 ,  C07D307/68 ,  C07D317/68 ,  C07D333/70 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/04 ,  C07D409/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/10 ,  C07D493/08 ,  C07D495/10 ,  C07D498/04 ,  C07D513/10 ,  Y02A50/30

Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

公开(公告)号：US20240000899A1

公开(公告)日：2024-01-04

申请号：US18200760

申请日：2023-05-23

Applicant: Tygrus, LLC

Inventor： Paul Bundschuh ,  Lawrence Carlson ,  Shawn Dolan

IPC: A61K38/40 ,  A61K31/185 ,  A61K9/00 ,  A61P31/04

CPC classification number: A61K38/40 ,  A61P31/04 ,  A61K9/0078 ,  A61K31/185

Abstract: A pharmaceutically acceptable therapeutic inhalation fluid that is composed of a fluid carrier and a pharmaceutically acceptable acid formulation present in the fluid carrier in an amount sufficient to provide a solution pH between 1.5 and 2.5, the pharmaceutically acceptable acid formulation having anti-bacterial, and/or anti-viral, and/or anti-fungal activity and at least one antimicrobial peptide.